May 20, 2025 | Clinical Trials Day, clinical trials
Understanding why people join clinical trials is essential to improving recruitment and designing better research. Explores the diverse motivations driving participation — from altruism and hope for better health to trusted recommendations, affordable care, and the desire for information.

For many, it’s not just about medicine, it’s about meaning and being part of something bigger. From seeking hope when faced with illness, to a desire to help others, the reasons people take part are as diverse as the people themselves. In a world where clinical breakthroughs depend on participation — understanding these motivations isn’t just important, it’s essential.
Knowing that their participation may advance medical knowledge and potentially help future generations, altruism can be a strong motivator for many patients. Many participants take part in a trial hoping to benefit others, even if their own condition may not improve.1 In a recent survey, 34% of respondents chose altruism as the main reason for taking part.2 This option was also particularly popular among patients with chronic conditions.2
Another strong motivator for many patients is the potential to improve their own health.3 Many participants are drawn to the opportunity to access potentially life-changing treatments, improve their quality of life, or achieve better health outcomes. Improving their quality of life was the number one reason for 33% of respondents, compared with 12% saying this was not a factor.3
For those with life-threatening conditions, the possibility of extending their life was even more significant. 55% of oncology participants reported life extension as the main reason for taking part, compared with just 8.8% of chronic/acute patients and 11.1% of chronic disease patients.3
Doctors, community leaders, including faith leaders, local advocates, and cultural influencers, often hold significant sway, especially within underserved or historically marginalised populations. By partnering with these trusted figures and educating them on what motivates people to join a clinical trial, sponsors can bridge gaps in trust and awareness, fostering greater participation among diverse communities.1,4
Whilst clinical trials can offer the opportunity to receive new treatments before they are widely available,5 many participants may be influenced by the affordable or free care. 25% of respondents highlighted access to cutting-edge therapies without high costs as a key motivator.3 This concern was consistent across socioeconomic groups, indicating access to affordable care is a universal concern.3
Similarly, financial compensation may be a determining factor. In one survey, 94.7% of patients who were in phase 1 studies identified financial compensation as a motivator for joining the trial.6
Logistics often play a significant role when patients are deciding whether to participate. Patients weigh up practical elements such as the time required, distance to trial sites, and the potential financial impact. In one study, 65% of patients said the required 8 visits over 16 weeks might stop them from participating. Many called it “difficult,” “inconvenient,” or “too much.”7 Reducing patient burden could help patients with practical concerns take part.
Some patients are curious to learn more about their condition and can view clinical trials as empowering. When patients are presented with clear, understandable information, they feel more confident in joining. Knowing the associated potential risks, benefits and their rights, including how their participation is voluntary, can encourage enrolment.8 However too much, or complex information may increase worries.1
To truly engage patients and create trust in clinical trials, recruitment strategies must move beyond basic outreach and reflect what matters most to participants.
When we listen to what truly matters to patients — their hopes, their fears, their realities — we don’t just improve recruitment. We build trials that reflect real lives, foster trust, and accelerate discoveries that save them. That’s why working this way isn’t optional — it’s the future of research. And it starts with how we recruit for tomorrow’s trials, today.
References
This content was provided by Cuttsy + Cuttsy